![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-desktop-w27gif-57924.gif)
![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-mobile-w27gif-62411.gif)
Active Filter(s):
Details:
The funding will be used to accelerate the development of Journey Colab’s portfolio of psychedelic compounds. Journey Colab’s lead compound, Mescaline HCl (JOUR-001), is being developed for the treatment of Alcohol Use Disorder (AUD).
Lead Product(s): Mescaline
Therapeutic Area: Psychiatry/Psychology Product Name: JOUR-001
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: MBX Capital
Deal Size: $12.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing September 07, 2021